STOCK TITAN

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) will participate in the Needham 23rd Annual Healthcare Conference and Piper Sandler Spring Biopharma Symposium to showcase advancements in rare disease treatments.
Positive
  • None.
Negative
  • None.

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.

 
Needham 23rd Annual Healthcare Conference
 Date: Monday, April 8, 2024
 Time: 9:30 AM ET
 Format: Corporate Presentation
 Webcast Link
  
Piper Sandler Spring Biopharma Symposium
 Date: Wednesday, April 17, 2024
 Format: 1x1 Meetings
  

About X4 Pharmaceuticals 
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a selective, small-molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. regulatory approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Contacts:
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Ché Knight (media)
LifeSci Communications
cknight@lifescicomms.com


FAQ

When is X4 Pharmaceuticals participating in the Needham 23rd Annual Healthcare Conference?

X4 Pharmaceuticals will participate in the Needham 23rd Annual Healthcare Conference on Monday, April 8, 2024.

What is the format of X4 Pharmaceuticals' presentation at the Needham 23rd Annual Healthcare Conference?

X4 Pharmaceuticals will have a corporate presentation at the Needham 23rd Annual Healthcare Conference on Monday, April 8, 2024, at 9:30 AM ET.

When is X4 Pharmaceuticals participating in the Piper Sandler Spring Biopharma Symposium?

X4 Pharmaceuticals will participate in the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024.

What is the format of X4 Pharmaceuticals' participation in the Piper Sandler Spring Biopharma Symposium?

X4 Pharmaceuticals will engage in 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024.

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

XFOR Rankings

XFOR Latest News

XFOR Stock Data

181.37M
130.20M
0.83%
61.32%
7.34%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About XFOR

x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t